32 results on '"Lingvay, Ildiko"'
Search Results
2. Effectiveness of semaglutide versus liraglutide for treating post‐metabolic and bariatric surgery weight recurrence
3. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The <scp>STEP</scp> 1 trial extension
4. Patterns of new glucagon‐like peptide‐1 receptor agonist use in patients with type 2 diabetes during 2014–2019 from a US database: prescriber and patient characteristics
5. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS ‐1 to ‐5 studies
6. Effects of once‐weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN‐6 trial
7. Associations of liver fat content with cardiometabolic phenotypes and outcomes in a multi‐ethnic population: Results from the Dallas Heart Study
8. Semaglutide for the treatment of overweight and obesity: A review
9. Rationale and design of the phase 3a development programme (ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes
10. Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
11. An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg
12. Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study
13. Back Cover Image, Volume 93, Number 7, July 2021
14. Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy
15. Pharmacotherapies for Post‐Bariatric Weight Regain: Real‐World Comparative Outcomes
16. Outpatient metformin use is associated with reduced severity of COVID‐19 disease in adults with overweight or obesity
17. Lactic acidosis incidence with metformin in patients with type 2 diabetes and chronic kidney disease: A retrospective nested case‐control study
18. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
19. Long‐Term Outcomes of Thyroid Nodule AFIRMA GEC Testing and Literature Review: An Institutional Experience
20. Cover Image, Volume 22, Issue 3
21. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
22. A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal‐bolus insulin or a glucagon‐like peptide‐1 receptor agonist plus basal insulin: The SIMPLE study
23. Roux‐en‐Y gastric bypass compared with equivalent diet restriction: Mechanistic insights into diabetes remission
24. The impact of bariatric surgery on cerebral vascular reactivity
25. When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy
26. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
27. Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial
28. Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used
29. The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin
30. Quantification of renal steatosis in type II diabetes mellitus using dixon-based MRI
31. Effect of pioglitazone on plasma ceramides in adults with metabolic syndrome
32. Pancreatic triglyceride levels: implications for type 2 diabetes development in ethnic minorities
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.